CN105125697A - Novel application of drug composition - Google Patents
Novel application of drug composition Download PDFInfo
- Publication number
- CN105125697A CN105125697A CN201510633866.0A CN201510633866A CN105125697A CN 105125697 A CN105125697 A CN 105125697A CN 201510633866 A CN201510633866 A CN 201510633866A CN 105125697 A CN105125697 A CN 105125697A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- radix
- group
- ganoderma
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses novel application of a drug composition for treating depression. The drug composition comprises 15-25 g of lucid ganoderma, 8-15 g of silkworm excrement, 6-20 g of periostracum cicada, 10-20 g of cassia seeds, 5-15 g of radix bupleuri, 6-18 g of golden cypress, 6-15 g of Chinese parsnip roots and 5-20 g of liquorice.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition being used for the treatment of the novelty teabag of depression, belonging to medical art.
Background technology
Depression (depression) be one group with the low syndrome for principal character of remarkable and lasting mental state, be one of common mental sickness, main manifestations is depressed, and interest lowers, pessimistic, retardation of thinking, lacks initiative, and self-accusation is from crime, diet, sleep poor, worry oneself to suffer from various disease, feeling that whole body many places are uncomfortable, can there is suicidal thought and behavior in severe patient.Depression has become the leading killer of 21 century human psychology disease, and society need be caused to pay much attention to.
The cause and onset of disease mechanism of depression is intricate, illustrates not yet completely.At present, conventional antidepressant drug mainly contains serotonin reuptake inhibitor (SSRIS), 5-hydroxy tryptamine and adrenalectomy element reuptake inhibitor (SNaRI), selectivity 5-hydroxy tryptamine and adrenalectomy element reuptake inhibitor (NaSSAS), dopamine reuptalce inhibitor (DA), selectivity NRI (NaRI) etc.The modal untoward reaction of these medicines is 5-HT syndrome, gastrointestinal reaction, sexual dysfunction, syndrome of inappropriate secretion of antidiuretic hormone, withdrawal symptom etc.There is significant hysteresis in most antidepressants, have impact on the performance of therapeutic effect and add side effect in clinical treatment.Depression is chronic disease, needs long-term prescription, must consider antidepressants long-term tolerance and with the problem such as the interactional safety of other drug.Long-term practice through inventor draws, treatment by Chinese herbs depression has good curative effect.
Therefore, provide that a kind of prescription is simple, herb resource is easy to get, Cure of depression is effective, effective percentage is high, mild in medicine property and, the Chinese medicine preparation that has no side effect, be the current technical issues that need to address.
Summary of the invention
Pharmaceutical composition is at the novelty teabag for the preparation of Cure of depression, and described pharmaceutical composition comprises: Ganoderma 15-25g, silkworm excrement 8-15g, Periostracum Cicadae 6-20g, Semen Cassiae 10-20g, Radix Bupleuri 5-15g, Cortex Phellodendri 6-18g, Radix Saposhnikoviae 6-15g, Radix Glycyrrhizae 5-20g.
Preferably, described pharmaceutical composition comprises: Ganoderma 18-23g, silkworm excrement 10-15g, Periostracum Cicadae 8-18g, Semen Cassiae 12-16g, Radix Bupleuri 6-13g, Cortex Phellodendri 8-16g, Radix Saposhnikoviae 8-13g, Radix Glycyrrhizae 8-16g.
Further preferably, described pharmaceutical composition comprises: Ganoderma 18-20g, silkworm excrement 12-15g, Periostracum Cicadae 9-16g, Semen Cassiae 12-15g, Radix Bupleuri 7-10g, Cortex Phellodendri 10-14g, Radix Saposhnikoviae 10-12g, Radix Glycyrrhizae 10-16g.
Further preferably, described pharmaceutical composition comprises: Ganoderma 20g, silkworm excrement 12g, Periostracum Cicadae 9g, Semen Cassiae 12g, Radix Bupleuri 10g, Cortex Phellodendri 14g, Radix Saposhnikoviae 12g, Radix Glycyrrhizae 10g.
Prescription provided by the invention is simple, and herb resource is easy to get, and Cure of depression is effective, and efficiency is high, natural, has no side effect.
The property of medicine and effect of Chinese crude drug of the present invention are as follows:
Ganoderma: be the sporophore of Polyporaceae plant epiphyte Ganoderma or On Polyporaceae Ganoderma lucidum (Leyss. Ex Fr.) Karst..Property is put down, sweet in the mouth.GUIXIN warp, lung meridian, Liver Channel, kidney channel.There is invigorating QI and tranquilization, cough and asthma relieving efficacy.
Silkworm excrement: the dry feces of Bombycidae insecticide silkworm B larva.Warm in nature, sweet in the mouth, pungent.Return Liver Channel, spleen channel, stomach warp.Expelling wind and removing dampness, regulating the function of the stomach to resolve the turbidity.
Periostracum Cicadae: exuviae shell when the nymph of cicada Cryptotympana atrata Fabr. sprouts wings.Cold in nature, sweet in the mouth.Return lung meridian, Liver Channel.Loose wind heat extraction, sore-throat relieving rash, spasmolytic, nebula removing.
Semen Cassiae: the mature seed of leguminous plant Semen Cassiae.Cold nature, bitter in the mouth, sweet; Return Liver Channel, kidney channel, large intestine channel; There is clearing away heat to improve acuity of vision, loosening bowel to relieve constipation.
Radix Bupleuri: the root cold nature of samphire Radix Bupeuri Scorzonerfolii., bitter in the mouth; Return Liver Channel, gallbladder meridian.There is reconciling superficies and interior, soothing the liver, yang invigorating effect.
Cortex Phellodendri: the bark of rutaceae wampee.Cold in nature, bitter in the mouth.Return kidney channel, urinary bladder channel.There is heat clearing and damp drying, pathogenic fire purging except steaming, detoxification sore treatment effect.
Radix Saposhnikoviae: the root of umbelliferae Saposhnikovia divaricata.Warm in nature, sweet in the mouth, pungent.Urinary bladder channel, Liver Channel, spleen channel is returned to have the effect delivered, dispel the wind, dehumidify.
Radix Glycyrrhizae: the dry root and rhizome deriving from glycyrrhizic legume, Glycyrrhiza inflata Bat. GlycyrrhizainflataBat. or Glycyrrhiza glabra L..Property is put down, sweet in the mouth.GUIXIN warp, stomach warp, spleen channel, lung meridian.Invigorating the spleen and replenishing QI, eliminating phlegm and stopping cough, emergency analgesic therapy, the property of medicine that is in harmonious proportion.
Compared with prior art, the invention has the beneficial effects as follows:
The present invention with the Ganoderma of invigorating QI and tranquilization for monarch drug, with silkworm excrement, Periostracum Cicadae for ministerial drug; With Semen Cassiae, Radix Bupleuri for adjuvant drug, with Radix Glycyrrhizae for making medicine, all medicines share, and play altogether to clear away heart-fire relieving convulsion, calm the nerves, the effect of resolving depression, are applicable to the treatment of depression.
The present invention affects mouse forced swimming test and outstanding tail by pharmaceutical composition to test the motionless time and affect that reserpine causes blepharoptosis, mouse temperature reduces and behavioristics's defect Experiment on Function, analyzes pharmaceutical composition senior middle school low dose group to the curative effect of depression.
Result of study shows: senior middle school's low dose group of pharmaceutical composition, obviously can shorten the dead time of mouse forced swimming test and outstanding tail; Antagonism reserpine causes mice blepharoptosis, body temperature reduces and behavioristics's defect effect.Also observe, pharmaceutical composition significantly can shorten the dead time of mouse forced swimming test and outstanding tail simultaneously, and significantly antagonism reserpine causes mice blepharoptosis, body temperature reduces and behavioristics's defect effect, and optimum with middle dosage, low dose group is the poorest.
Detailed description of the invention
Below in conjunction with detailed description of the invention; claim of the present invention is described in further detail; but do not form any limitation of the invention, any limited amendment made within the scope of the claims in the present invention, still within claims of the present invention.
Embodiment 1
A kind of pharmaceutical composition of Cure of depression: Ganoderma 15g, silkworm excrement 8g, Periostracum Cicadae 6g, Semen Cassiae 10g, Radix Bupleuri 5g, Cortex Phellodendri 6g, Radix Saposhnikoviae 6g, Radix Glycyrrhizae 5g.
Embodiment 2
A kind of pharmaceutical composition of Cure of depression: Ganoderma 20g, silkworm excrement 12g, Periostracum Cicadae 9g, Semen Cassiae 12g, Radix Bupleuri 10g, Cortex Phellodendri 14g, Radix Saposhnikoviae 12g, Radix Glycyrrhizae 10g.
Embodiment 3
A kind of pharmaceutical composition of Cure of depression: Ganoderma 25g, silkworm excrement 15g, Periostracum Cicadae 20g, Semen Cassiae 20g, Radix Bupleuri 15g, Cortex Phellodendri 18g, Radix Saposhnikoviae 15g, Radix Glycyrrhizae 20g.
Embodiment 4
A kind of pharmaceutical composition of Cure of depression: Ganoderma 18g, silkworm excrement 12g, Periostracum Cicadae 18g, Semen Cassiae 15g, Radix Bupleuri 15g, Cortex Phellodendri 12g, Radix Saposhnikoviae 13g, Radix Glycyrrhizae 10g.
Embodiment 5
Laboratory animal: mice, male and female half and half, SPF level, body weight (20 ± 2) g, all animal quiet environment are raised, and freely take food drinking-water, artificial circadian rhythm (12h-12h).
Reagent: normal saline
Medicine: reserpine injection
Contrast medicine: amitriptyline hydrochloride tablet (Pharmaceutical Co Ltd, Changzhou Pharmaceutical Factory No.4)
Investigational agent: by the homemade Chinese medical concrete of prescription in embodiment 2.
Instrument: superclean bench, syringe, instrument quasiconductor thermometer; Wooden case (40cm × 40cm × 40cm, long × wide × high) (self-control); Outstanding tail support (self-control).
Test 1: on the impact of mouse forced swimming test dead time
50 mices are divided into 5 groups at random, i.e. matched group (normal saline 25gkg-1), amitriptyline hydrochloride tablet group (35mgkg-1), the high, medium and low dosage group of pharmaceutical composition (35,20,12gkg-1).7d ig administration in advance before experiment, qd; Matched group ig normal saline (25gkg-1).60min after last administration, puts into the container of depth of water 10cm respectively by each group of mice, water temperature 25 DEG C.Observe 6min, observe and dead time in 4min after recording each group of mice.
Result of study shows:
The motionless state that mice occurs in forced swimming model reflects the desperate behavior of animal, and pharmaceutical composition can significantly shorten the mouse forced swimming test dead time.The results are shown in Table 1.
Table 1
Test 2: on the impact of mouse tail suspension dead time
50 mices are divided into 5 groups at random, i.e. matched group (normal saline 25gkg-1), amitriptyline hydrochloride tablet group (35mgkg-1), the high, medium and low dosage group of pharmaceutical composition (35,20,12gkg-1).7d ig administration in advance before experiment, qd; Matched group ig normal saline 25gkg-1.60min after last administration, is affixed on the part at mouse tail 2cm place on outstanding tail support, makes animal be reversal of the natural order of things state, and its head destage face is about 5cm, and hang both sides plate and separate animal sight line, observed and recorded respectively organizes mice dead time in 6min.
Result of study shows:
The each dosage group of pharmaceutical composition all significantly can shorten tail like chain stress dead time of mice.The results are shown in Table 2
Table 2
Test 3: Reserpine antagonistic test
60 mices are divided into 6 groups at random, i.e. normal group, model group, amitriptyline hydrochloride tablet group (35mgkg-1), the high, medium and low dosage group of pharmaceutical composition (35,20,12gkg-1).7d ig administration in advance before experiment, qd, normal group and model group ig normal saline 25gkg-1.60min after last administration, mouse peritoneal injection 2.5mgkg-1 reserpine, observe respectively after 1h:
1. respectively organize mice blepharoptosis degree, and add up in the mode of score, scoring criterion is: widening the view completely is 0 point, and 1/4 eye closing is 1 point, and 1/2 eye closing is 2 points, and 3/4 eye closing is 3 points, and closing one's eyes completely is 4 points.
2. probe is inserted animal anal 1.5 ~ 2cm place and measure anus temperature, compare the difference of administration group and the change of matched group anus temperature, and the difference of administration group and the change of matched group anus temperature after measuring lumbar injection reserpine 4h.
3. Open field activity: experimental provision is 40cm × 40cm × 40cm (length × wide x is high) wooden case, and bottom is divided into 25 grids, spontaneous activity in mice in record 5min.Observation index: step on lattice number (more than three-jaw striding into the number of times of adjacent lattice) and modify number of times (number of times of liftoff more than the 1cm of two forelimbs).
Result of the test is as follows:
On the impact that reserpine causes mouse temperature to decline
After injection reserpine 1h, namely mouse temperature starts to decline, and each administration group body temperature when 1h compares there was no significant difference with normal group; After 4h, each dosage group energy of the pharmaceutical composition mouse temperature that significantly antagonism reserpine causes declines.The results are shown in Table 3.
Table 3
Reserpine is caused to the impact of mice blepharoptosis
The mice blepharoptosis effect that each dosage group of pharmaceutical composition has antagonism reserpine to cause.The results are shown in Table 4.
Table 4
Injection reserpine is caused to the impact of mice behavior defect (Open field activity)
The obvious defect of mice behavior after reserpine injection.Compare with model group, the meansigma methods that each group of pharmaceutical composition and amitriptyline hydrochloride tablet group step on grid number has the trend increased, and in pharmaceutical composition dosage group energy significance improve mice step on grid number; Modification number of times and the model group of pharmaceutical composition senior middle school low dose group compare, and obviously increase, have significant difference.Experimental result is in table 5.
Table 5
Claims (5)
1. a pharmaceutical composition is at the novelty teabag for the preparation of Cure of depression, it is characterized in that, described pharmaceutical composition comprises: Ganoderma 15-25g, silkworm excrement 8-15g, Periostracum Cicadae 6-20g, Semen Cassiae 10-20g, Radix Bupleuri 5-15g, Cortex Phellodendri 6-18g, Radix Saposhnikoviae 6-15g, Radix Glycyrrhizae 5-20g.
2. application according to claim 1, is characterized in that, described pharmaceutical composition comprises: Ganoderma 18-23g, silkworm excrement 10-15g, Periostracum Cicadae 8-18g, Semen Cassiae 12-16g, Radix Bupleuri 6-13g, Cortex Phellodendri 8-16g, Radix Saposhnikoviae 8-13g, Radix Glycyrrhizae 8-16g.
3. application according to claim 2, is characterized in that, described pharmaceutical composition comprises: Ganoderma 18-20g, silkworm excrement 12-15g, Periostracum Cicadae 9-16g, Semen Cassiae 12-15g, Radix Bupleuri 7-10g, Cortex Phellodendri 10-14g, Radix Saposhnikoviae 10-12g, Radix Glycyrrhizae 10-16g.
4. application according to claim 3, is characterized in that, described pharmaceutical composition comprises: Ganoderma 20g, silkworm excrement 12g, Periostracum Cicadae 9g, Semen Cassiae 12g, Radix Bupleuri 10g, Cortex Phellodendri 14g, Radix Saposhnikoviae 12g, Radix Glycyrrhizae 10g.
5. the application according to any one of claim 1-4, is characterized in that, described pharmaceutical composition can be used for preparing Cure of depression.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510633866.0A CN105125697A (en) | 2015-09-26 | 2015-09-26 | Novel application of drug composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510633866.0A CN105125697A (en) | 2015-09-26 | 2015-09-26 | Novel application of drug composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105125697A true CN105125697A (en) | 2015-12-09 |
Family
ID=54711511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510633866.0A Pending CN105125697A (en) | 2015-09-26 | 2015-09-26 | Novel application of drug composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105125697A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106938039A (en) * | 2017-03-29 | 2017-07-11 | 卢仁华 | The medicine of ptosis |
-
2015
- 2015-09-26 CN CN201510633866.0A patent/CN105125697A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106938039A (en) * | 2017-03-29 | 2017-07-11 | 卢仁华 | The medicine of ptosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100350925C (en) | Novel snuff aerosol | |
| CN103405668B (en) | Medicament for treating arrhythmia | |
| CN103405716A (en) | Herbal decoction for treating insomnia | |
| CN101579186B (en) | Pharmaceutical rhinitis pillow for external use and treating wind-heat rhinitis | |
| CN102526677B (en) | Chinese medicine foot-massage composition for treating common cold due to wind-cold | |
| CN101288761B (en) | Chinese tmedicine preparation for treating depression and its preparation method | |
| CN100394933C (en) | Application of 'Guizhi Gancao Longgu Muli' preparation in preparation of medicine for preventing and treating depression | |
| CN105125697A (en) | Novel application of drug composition | |
| CN102579818B (en) | Traditional Tibetan medicine composition, preparation method thereof and application | |
| CN105616839B (en) | A kind of herbal medicine efficacy component compound with antidepressant effect | |
| CN101658573A (en) | Chinese herba preparation for treating depression | |
| CN103798472B (en) | A kind of health protection tea and health care's preparation | |
| CN105662036A (en) | Lignum santali albi, aquilaria agallocha and cinnamomum camphora redwood pillow | |
| CN105232716A (en) | Extraction method of Anti-depression composition | |
| CN104435798A (en) | Traditional Chinese medicine preparation for improving neurasthenia and preparation method thereof | |
| CN103099877B (en) | Traditional Chinese medicine formula for treating and preventing children asthmatic disease | |
| CN103007171B (en) | Traditional Chinese medicine composition for curing remitted schizophrenia and preparing method of traditional Chinese medicine composition | |
| CN105770563A (en) | Traditional Chinese medicine preparation for treating anxiety disorder and preparation method for traditional Chinese medicine preparation | |
| CN105596810A (en) | Traditional Chinese medicinal composition for preventing depression, and preparation method thereof | |
| CN105106651A (en) | Traditional Chinese medicine for treating clear qi failing to ascend type nerve deafness | |
| CN105343188A (en) | Drug combination with cough relieving function | |
| CN104825536A (en) | Novel application of pharmaceutical composition in preparation of drugs for treating depression | |
| CN104825732A (en) | Traditional Chinese medicine composition for treating palpitaition | |
| CN104383157B (en) | Pharmaceutical composition for treating simple hidrosis of children | |
| CN104189314A (en) | Pharmaceutical composition for treating hyperlipidemia with phlegm and turbid repression syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151209 |